Biomedical Engineering Reference
In-Depth Information
Joseph K, Mantrala M (2009) A model of the role of free drug samples in physicians' prescription
decisions. Mark Lett 20(1):15-29
Kaiser Family Foundation (2010) U.S. health care costs: background brief.
http://www.kaiseredu.
org/Issue-Modules/US-Health-Care-Costs/Background-Brief.aspx
.
Accessed 11 Nov 2011
Kalyanaram G, Robinson WT, Urban GL (1995) Order of market entry: established empirical
generalizations, emerging empirical generalizations, and future research. Mark Sci 14(3):
G212-G221
Keller J, Pauwels K (2009) Managing across substitute categories—changing pharmaceutical mar-
keting elasticities and budget allocation. Working paper, Dartmouth College
Kolsarici C, Vakratsas D (2010) Category- versus brand-level advertising messages in a highly
regulated environment. J Mark Res 47(6):1078-1089
Kremer STM, Bijmolt THA, Leefl ang PSH, Wieringa JE (2008) Generalizations on pharmaceuti-
cal marketing effectiveness. Int J Res Mark 25(4):234-246
Leefl ang PSH, Wieringa JE (2010) Modeling the effects of pharmaceutical marketing. Mark Lett
21(2):121-133
Leefl ang PSH, Mijatovic GM, Saunders J (1992) Identifi cation and estimation of complex multi-
variate lag structures—a nesting approach. Appl Econ 24(2):273-283
Leefl ang PSH, Wittink DR, Wedel M, Naert PA (2000) Building models for marketing decisions.
Kluwer Academic Publishers, Dordrecht
Leefl ang PSH, Bijmolt THA, van Doorn J, Hanssens DM, van Heerde HJ, Verhoef PC, Wieringa
JE (2009) Creating lift versus building the base: current trends in marketing dynamics. Int J Res
Mark 26(1):13-20
Leffl er KB (1981) Persuasion or information? The economics of prescription drug advertising.
J Law Econ 24(1):45-74
Lieberman MB, Montgomery DB (1988) First-mover advantages. Strat Manag J 9(Special
Issue):41-58
Lilien GL, Rao AG, Kalish S (1981) Bayesian estimation and control of detailing effort in a repeat-
purchase diffusion environment. Manag Sci 27(5):493-506
Mahajan V, Muller E (1979) Innovation diffusion and new product growth models in marketing.
J Mark 43(4):55-68
Mahajan V, Wind Y (1986) Innovation diffusion models of new product acceptance. Ballinger
Publishing Company, Cambridge, MA
Mahajan V, Muller E, Bass FM (1990) New product diffusion models in marketing: a review and
directions for future research. J Mark 54(1):1-26
Mahajan V, Muller E, Wind Y (2000) New-product diffusion models. Kluwer Academic Publishers,
Dordrecht
Mahecha LA (2006) Rx-to-OTC switches: trends and factors underlying success. Nat Rev Drug
Discov 5(5):380-386
Manchanda P, Honka E (2005) The effects and role of direct-to-physician marketing in the phar-
maceutical industry: an integrative review. Yale J Health Policy Law Ethics 5(2):785-822
Manchanda P, Wittink DR, Ching A, Cleanthous P, Ding M, Dong XJ, Leefl ang PSH, Misra S,
Mizik N, Narayanan S, Steenburgh T, Wieringa JE, Wosinska M, Xie Y (2005) Understanding
fi rm, physician and consumer choice behavior in the pharmaceutical industry. Mark Lett
16(3-4):293-308
Meade N, Islam T (2006) Modelling and forecasting the diffusion of innovation—a 25-year review.
Int J Forecast 22(3):519-545
Montgomery DB, Silk AJ (1972) Estimating dynamic effects of market communications expendi-
tures. Manag Sci 18(10):B-485-B-501
Murphy MN, Smith MC, Juergens JP (1992) The synergic impact of promotion intensity and thera-
peutic novelty on market performance of prescription drugs. J Drug Issues 22(2):305-316
Narayanan S, Desiraju R, Chintagunta PK (2004) Return on investment implications for pharma-
ceutical promotional expenditures: the role of marketing-mix interactions. J Mark 68(4):
90-105
Search WWH ::
Custom Search